Logo image of LRMR

LARIMAR THERAPEUTICS INC (LRMR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LRMR - US5171251003 - Common Stock

3.665 USD
-0.15 (-3.81%)
Last: 1/2/2026, 9:46:47 AM
Fundamental Rating

2

Taking everything into account, LRMR scores 2 out of 10 in our fundamental rating. LRMR was compared to 530 industry peers in the Biotechnology industry. While LRMR seems to be doing ok healthwise, there are quite some concerns on its profitability. LRMR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LRMR has reported negative net income.
In the past year LRMR has reported a negative cash flow from operations.
LRMR had negative earnings in each of the past 5 years.
LRMR had a negative operating cash flow in each of the past 5 years.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of LRMR (-70.46%) is worse than 62.64% of its industry peers.
LRMR has a Return On Equity (-94.94%) which is in line with its industry peers.
Industry RankSector Rank
ROA -70.46%
ROE -94.94%
ROIC N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LRMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, LRMR has more shares outstanding
LRMR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LRMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.31, we must say that LRMR is in the distress zone and has some risk of bankruptcy.
LRMR's Altman-Z score of -0.31 is in line compared to the rest of the industry. LRMR outperforms 59.06% of its industry peers.
LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.31
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

LRMR has a Current Ratio of 4.06. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
LRMR has a Current ratio of 4.06. This is comparable to the rest of the industry: LRMR outperforms 48.87% of its industry peers.
LRMR has a Quick Ratio of 4.06. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
LRMR has a Quick ratio (4.06) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 4.06
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LRMR have decreased strongly by -67.83% in the last year.
EPS 1Y (TTM)-67.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-154.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LRMR will show a decrease in Earnings Per Share. The EPS will decrease by -6.79% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-54.11%
EPS Next 2Y-21.29%
EPS Next 3Y-8.17%
EPS Next 5Y-6.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LRMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LRMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as LRMR's earnings are expected to decrease with -8.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.29%
EPS Next 3Y-8.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LRMR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (1/2/2026, 9:46:47 AM)

3.665

-0.15 (-3.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners99.12%
Inst Owner Change29.88%
Ins Owners1.02%
Ins Owner Change0%
Market Cap313.69M
Revenue(TTM)N/A
Net Income(TTM)-132.00M
Analysts88.89
Price Target16.97 (363.03%)
Short Float %9.44%
Short Ratio5.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.87%
Min EPS beat(2)-48.03%
Max EPS beat(2)16.29%
EPS beat(4)1
Avg EPS beat(4)-19.67%
Min EPS beat(4)-48.03%
Max EPS beat(4)16.29%
EPS beat(8)2
Avg EPS beat(8)-10.27%
EPS beat(12)6
Avg EPS beat(12)-0.43%
EPS beat(16)10
Avg EPS beat(16)4.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.28%
EPS NQ rev (1m)-0.55%
EPS NQ rev (3m)-19.77%
EPS NY rev (1m)-18.32%
EPS NY rev (3m)-17.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.46%
ROE -94.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.06
Quick Ratio 4.06
Altman-Z -0.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)82.04%
Cap/Depr(5y)77.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-154.17%
EPS Next Y-54.11%
EPS Next 2Y-21.29%
EPS Next 3Y-8.17%
EPS Next 5Y-6.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.02%
EBIT Next 3Y-22.03%
EBIT Next 5Y25.77%
FCF growth 1Y-214.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-213.4%
OCF growth 3YN/A
OCF growth 5YN/A

LARIMAR THERAPEUTICS INC / LRMR FAQ

What is the fundamental rating for LRMR stock?

ChartMill assigns a fundamental rating of 2 / 10 to LRMR.


What is the valuation status for LRMR stock?

ChartMill assigns a valuation rating of 0 / 10 to LARIMAR THERAPEUTICS INC (LRMR). This can be considered as Overvalued.


What is the profitability of LRMR stock?

LARIMAR THERAPEUTICS INC (LRMR) has a profitability rating of 0 / 10.


What is the earnings growth outlook for LARIMAR THERAPEUTICS INC?

The Earnings per Share (EPS) of LARIMAR THERAPEUTICS INC (LRMR) is expected to decline by -54.11% in the next year.